Jefferies Financial Group Issues Positive Forecast for Compass Therapeutics (NASDAQ:CMPX) Stock Price

Compass Therapeutics (NASDAQ:CMPX) had its price objective raised by Jefferies Financial Group from $7.00 to $8.00 in a research note released on Monday morning,Benzinga reports. They currently have a buy rating on the stock.

Several other equities analysts have also commented on the company. D. Boral Capital reiterated a “buy” rating and issued a $32.00 target price on shares of Compass Therapeutics in a research note on Wednesday, January 8th. Leerink Partnrs downgraded shares of Compass Therapeutics from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 15th. Leerink Partners cut shares of Compass Therapeutics from an “outperform” rating to a “market perform” rating and decreased their target price for the stock from $5.00 to $4.00 in a research report on Friday, November 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $10.00 price target on shares of Compass Therapeutics in a research report on Wednesday, January 8th. Two equities research analysts have rated the stock with a hold rating and five have given a buy rating to the company’s stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average price target of $11.17.

Compass Therapeutics Stock Performance

Shares of CMPX opened at $3.75 on Monday. Compass Therapeutics has a 1 year low of $0.76 and a 1 year high of $4.08. The company’s 50 day simple moving average is $2.20 and its 200 day simple moving average is $1.77. The company has a market capitalization of $515.96 million, a price-to-earnings ratio of -10.13 and a beta of 1.17.

Compass Therapeutics (NASDAQ:CMPX) last issued its quarterly earnings results on Tuesday, November 12th. The company reported ($0.08) earnings per share for the quarter, beating the consensus estimate of ($0.11) by $0.03. Equities analysts expect that Compass Therapeutics will post -0.35 EPS for the current fiscal year.

Hedge Funds Weigh In On Compass Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of CMPX. Renaissance Technologies LLC raised its holdings in Compass Therapeutics by 99.7% in the second quarter. Renaissance Technologies LLC now owns 140,600 shares of the company’s stock valued at $141,000 after buying an additional 70,200 shares during the period. Cubist Systematic Strategies LLC purchased a new position in shares of Compass Therapeutics in the 2nd quarter valued at $41,000. SG Americas Securities LLC raised its stake in shares of Compass Therapeutics by 16.6% in the 3rd quarter. SG Americas Securities LLC now owns 38,665 shares of the company’s stock valued at $71,000 after acquiring an additional 5,515 shares during the period. Rovin Capital UT ADV acquired a new position in shares of Compass Therapeutics during the 3rd quarter valued at $25,000. Finally, Intech Investment Management LLC purchased a new stake in Compass Therapeutics during the 3rd quarter worth $30,000. 68.43% of the stock is owned by institutional investors and hedge funds.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.